Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Antistaphylococcal activity of dalbavancin, an experimental glycopeptide.

Literature DB >> 15673763

Antistaphylococcal activity of dalbavancin, an experimental glycopeptide.

Gengrong Lin¹, Kim Credito, Lois M Ednie, Peter C Appelbaum.

Abstract

Dalbavancin, tested against 146 staphylococci, was more potent than other drugs tested, with an MIC at which 50% of staphylococci were inhibited of 0.03 microg/ml and an MIC at which 90% of staphylococci were inhibited of 0.06 microg/ml by microdilution. For all strains, MICs of vancomycin, linezolid, ranbezolid, oritavancin, daptomycin, and quinupristin-dalfopristin were </=4.0 microg/ml. Dalbavancin was bactericidal at four times the MIC against all six strains tested.

Entities: Chemical

Mesh：

Substances：

Year: 2005 PMID： 15673763 PMCID： PMC547276 DOI： 10.1128/AAC.49.2.770-772.2005

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

24 in total

1. Initial quality control evaluations for susceptibility testing of Dalbavancin (BI397), an investigational glycopeptide with potent gram-positive activity.

Authors: Tamara R Anderegg; Douglas J Biedenbach; Ronald N Jones
Journal: J Clin Microbiol Date: 2003-06 Impact factor: 5.948

2. In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates.

Authors: E Cercenado; F García-Garrote; E Bouza
Journal: J Antimicrob Chemother Date: 2001-01 Impact factor: 5.790

3. In vitro activities of six quinolones and mechanisms of resistance in Staphylococcus aureus and coagulase-negative staphylococci.

Authors: H J Linde; M Schmidt; E Fuchs; U Reischl; H H Niller; N Lehn
Journal: Antimicrob Agents Chemother Date: 2001-05 Impact factor: 5.191

4. Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group.

Authors: C J Henwood; D M Livermore; A P Johnson; D James; M Warner; A Gardiner
Journal: J Antimicrob Chemother Date: 2000-12 Impact factor: 5.790

5. Antipneumococcal and antistaphylococcal activities of ranbezolid (RBX 7644), a new oxazolidinone, compared to those of other agents.

Authors: Dianne B Hoellman; Gengrong Lin; Lois M Ednie; Ashok Rattan; Michael R Jacobs; Peter C Appelbaum
Journal: Antimicrob Agents Chemother Date: 2003-03 Impact factor: 5.191

6. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center.

Authors: Bulent Bozdogan; Duygu Esel; Cynthia Whitener; Frederick A Browne; Peter C Appelbaum
Journal: J Antimicrob Chemother Date: 2003-10-16 Impact factor: 5.790

7. In vitro activities of dalbavancin and nine comparator agents against anaerobic gram-positive species and corynebacteria.

Authors: Ellie J C Goldstein; Diane M Citron; C Vreni Merriam; Yumi Warren; Kerin Tyrrell; Helen T Fernandez
Journal: Antimicrob Agents Chemother Date: 2003-06 Impact factor: 5.191

8. Bactericidal activity of daptomycin against Streptococcus pneumoniae compared with eight other antimicrobials.

Authors: Glenn A Pankuch; Michael R Jacobs; Peter C Appelbaum
Journal: J Antimicrob Chemother Date: 2003-02 Impact factor: 5.790

9. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections.

Authors: Elyse Seltzer; Mary Beth Dorr; Beth P Goldstein; Marc Perry; James A Dowell; Tim Henkel
Journal: Clin Infect Dis Date: 2003-10-17 Impact factor: 9.079

10. In vitro evaluation of BI 397, a novel glycopeptide antimicrobial agent.

Authors: R N Jones; D J Biedenbach; D M Johnson; M A Pfaller
Journal: J Chemother Date: 2001-06 Impact factor: 1.714

25 in total

Review 1. Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens.

Authors: Biswadeep Das; Chayna Sarkar; Debasmita Das; Amit Gupta; Arnav Kalra; Shubham Sahni
Journal: Ther Adv Infect Dis Date: 2017-03-08

2. Factors influencing broth microdilution antimicrobial susceptibility test results for dalbavancin, a new glycopeptide agent.

Authors: Robert P Rennie; Laura Koeth; Ronald N Jones; Thomas R Fritsche; Cindy C Knapp; Scott B Killian; Beth P Goldstein
Journal: J Clin Microbiol Date: 2007-08-01 Impact factor: 5.948

3. Comparison of dalbavancin MIC values determined by Etest (AB BIODISK) and reference dilution methods using gram-positive organisms.

Authors: Thomas R Fritsche; Robert P Rennie; Beth P Goldstein; Ronald N Jones
Journal: J Clin Microbiol Date: 2006-08 Impact factor: 5.948

4. Bactericidal activity and resistance development profiling of dalbavancin.

Authors: Beth P Goldstein; Deborah C Draghi; Daniel J Sheehan; Patricia Hogan; Daniel F Sahm
Journal: Antimicrob Agents Chemother Date: 2007-01-12 Impact factor: 5.191

5. Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.

Authors: Eric G Solon; James A Dowell; Jonghui Lee; S Peter King; Bharat D Damle
Journal: Antimicrob Agents Chemother Date: 2007-06-04 Impact factor: 5.191

6. Dalbavancin (zeven), a novel glycopeptide for resistant gram-positive organisms.

Authors: Jennifer Colabella; Larisa Chagan
Journal: P T Date: 2008-01

7. In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections.

Authors: Ellie J C Goldstein; Diane M Citron; Yumi A Warren; Kerin L Tyrrell; C Vreni Merriam; Helen T Fernandez
Journal: Antimicrob Agents Chemother Date: 2006-08 Impact factor: 5.191